Routine
Notice
Added
Blood-brain barrier crossing MLL1-WDR5 inhibitor compounds
Detected
March 24th, 2026
Summary
Blood-brain barrier crossing MLL1-WDR5 inhibitor compounds
Source document (simplified)
BLOOD-BRAIN BARRIER CROSSING MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR COMPOUNDS AND USES THEREOF
Publication EP4493184A1 Kind: A1 Mar 18, 2026
Applicants
Huyabio International, LLC
Inventors
SHOJAEI, Farbod, FANG, Che, SEMPLE, J. Edward, GILLINGS, Mireille
IPC Classifications
A61K 31/496 20060101AFI20260209BHEP A61K 31/5377 20060101ALI20260209BHEP A61P 25/00 20060101ALI20260209BHEP A61P 35/00 20060101ALI20260209BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Source
Analysis generated by AI. Source diff and links are from the original.
Classification
Browse Categories
Agriculture & Food Safety
61
Banking & Finance
236
Consumer Protection
40
Courts & Legal
323
Data Privacy & Cybersecurity
64
Defense & National Security
48
Education
20
Energy
104
Environment
83
Government & Legislation
261
Healthcare
131
Housing
16
Immigration
9
Insurance
56
Labor & Employment
111
Legal & Courts
1
Pharma & Drug Safety
99
Securities & Markets
79
Tax
64
Telecom & Technology
47
Trade & Sanctions
124
Transportation
56
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Pharma (A61K) publishes new changes.